199538-99-3

Basic information

• Product Name: tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate
• Synonyms: tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate;1-Boc-4-(2-propyn-1-yl)piperazine;4-Prop-2-ynyl-piperazine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(prop-2-yn-1-yl)piperazine-1-carboxylate
• CAS NO: 199538-99-3
• Molecular Formula: C₁₂H₂₀N₂O₂
• Molecular Weight: 224.3
• Product Categories: pharmacetical
• Mol File: 199538-99-3.mol
• Article Data: 35

Chemical Properties

• Boiling Point: 292.8°C at 760 mmHg
• Flash Point: 130.9°C
• Appearance: /
• Density: 1.05g/cm³
• Vapor Pressure: 0.00179mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate(199538-99-3)
• EPA Substance Registry System: tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate(199538-99-3)

Safety Data

• Hazardous Substances Data: 199538-99-3(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 4-(prop-2-ynyl)piperazine-1-carboxylate, also known as CAS Number: 147506-05-0, is an organic compound characterized by the presence of piperazine and prop-2-ynyl groups. This chemical has a molecular formula of C12H20N2O2 and exhibits properties similar to other piperazine derivatives. It is often used in the research and development of new pharmaceutical products, given its potential bioactivity. However, specific information about its biological effects, toxicity, and overall safety is limited, signifying the need for careful handling and usage. Being a synthetic compound, it’s mainly prepared in a laboratory, rather than naturally occurring.

InChI:InChI=1/C12H20N2O2/c1-5-6-13-7-9-14(10-8-13)11(15)16-12(2,3)4/h1H,6-10H2,2-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 106-96-7 propargyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1354894-20-4 (S)-methyl 3-phenyl-2-(4-(prop-2-yn-1-yl)piperazine-1-carboxamido)propanoate 
• 1354894-21-5 (S)-3-phenyl-2-(4-(prop-2-yn-1-yl)piperazine-1-carboxamido)propanoic acid hydrochloride 
• 1354894-16-8 N-((S)-1-oxo-3-phenyl-1-(((S,E)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)amino)propan-2-yl)-4-(prop-2-yn-1-yl)piperazine-1-carboxamide 
• 1676893-24-5 2,4-difluoro-N-(2-methoxy-5-(4-(3-(4-(methylsulfonyl)piperazin-1-yl)prop-1-yn-1-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1620058-70-9 C₃₅H₄₁N₄O₂⁽¹⁺⁾*Cl^(1-) 
• 1457884-98-8 C₂₅H₂₈N₄O₂ 

Relevant articles and documents

Synthesis of macrolones with central piperazine ring in the linker and its influence on antibacterial activity

Three macrolides, clarithromycin, azithromycin and 11-O-Me-azithromycin have been selected for the construction of a series of new macrolone derivatives. Quinolone-linker intermediates are prepared by Sonogashira-type C(6)-alkynylation of 6-iodoquinolone precursors. The final macrolones, differing by macrolide moiety and substituents at the position N-1 of the quinolone or by the presence of an ethyl ester or free acid on the quinolone unit attached via a linker. The linker comprises of a central piperazine ring bonded to the 4″-O position of cladinose by 3-carbon ester or ether functionality. Modifications of the linker did not improve antibacterial properties compared to the previously reported macrolone compounds. Linker flexibility seems to play an important role for potency against macrolide resistant respiratory pathogens.

MDM2 DEGRADERS AND USES THEREOF

The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.